FATE - Fate Therapeutics treats first patient in early-stage FT819 trial

Fate Therapeutics (NASDAQ:FATE) announces that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. The multi-center Phase 1 trial is designed to determine the recommended Phase 2 dose and schedule of FT819 and assess its safety and clinical activity in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas (BCL). The first patient with relapsed / refractory ALL was enrolled in Regimen A and received a dose of 90 million cells.

For further details see:

Fate Therapeutics treats first patient in early-stage FT819 trial